58 related articles for article (PubMed ID: 31669811)
1. N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.
Su H; Xue Z; Feng Y; Xie Y; Deng B; Yao Y; Tian X; An Q; Yang L; Yao Q; Xue J; Chen G; Hao C; Zhou T
Toxicol Appl Pharmacol; 2019 Dec; 384():114789. PubMed ID: 31669811
[TBL] [Abstract][Full Text] [Related]
2. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
[TBL] [Abstract][Full Text] [Related]
3. QAP14 suppresses breast cancer stemness and metastasis via activation of dopamine D1 receptor.
Yong L; Yao Y; Chen GS; Yan XX; Guo YC; Han MY; Xue JS; Jian WZ; Zhou TY
Acta Pharmacol Sin; 2022 Apr; 43(4):1001-1012. PubMed ID: 34183757
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden.
Wang S; Zhu X; Han M; Hao F; Lu W; Zhou T
AAPS J; 2020 Feb; 22(2):45. PubMed ID: 32043246
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D
Yang L; Yao Y; Yong L; Feng Y; Su H; Yao Q; Xue J; Lu W; Zhou T
Eur J Pharmacol; 2019 Sep; 859():172499. PubMed ID: 31242439
[TBL] [Abstract][Full Text] [Related]
6. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Wang C; Yang A; Zhang B; Yin Q; Huang H; Chen M; Xie J
Pancreas; 2014 Mar; 43(2):291-7. PubMed ID: 24518510
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.
Kallifatidis G; Labsch S; Rausch V; Mattern J; Gladkich J; Moldenhauer G; Büchler MW; Salnikov AV; Herr I
Mol Ther; 2011 Jan; 19(1):188-95. PubMed ID: 20940707
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Xu XT; Chen J; Ren X; Ma YR; Wang X; Ma YY; Zhao DG; Zhou RP; Zhang K; Goodin S; Li DL; Zheng X
Eur J Pharmacol; 2021 Feb; 893():173840. PubMed ID: 33359649
[TBL] [Abstract][Full Text] [Related]
9. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft.
Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888
[TBL] [Abstract][Full Text] [Related]
11. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
12. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G
Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446
[TBL] [Abstract][Full Text] [Related]
13. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
14. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
[TBL] [Abstract][Full Text] [Related]
15. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft.
Hao F; Wang S; Zhu X; Xue J; Li J; Wang L; Li J; Lu W; Zhou T
Pharm Res; 2017 Feb; 34(2):408-418. PubMed ID: 27975187
[TBL] [Abstract][Full Text] [Related]
17. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
18. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia.
Skaraitė I; Maccioni E; Petrikaitė V
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982496
[TBL] [Abstract][Full Text] [Related]
20. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.
Ponnurangam S; Dandawate PR; Dhar A; Tawfik OW; Parab RR; Mishra PD; Ranadive P; Sharma R; Mahajan G; Umar S; Weir SJ; Sugumar A; Jensen RA; Padhye SB; Balakrishnan A; Anant S; Subramaniam D
Oncotarget; 2016 Jan; 7(3):3217-32. PubMed ID: 26673007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
